Johnson & Johnson reported third-quarter sales of $25.4 billion, up 5.9% from a year earlier, and raised its full-year 2026 guidance. The healthcare group now expects reported annual sales of about $101.2 billion and adjusted earnings per share of roughly $11.10 at the midpoint. Despite the stronger overall outlook, shares fell as investors focused on weaker-than-expected medical-device sales, particularly outside the United States.
Overall sales grew 5.9%
Reported sales rose to $25.399 billion from $23.993 billion a year earlier. Operational growth was 6%, while adjusted operational growth was 6.1%.
The diversified structure of pharmaceuticals and medical technology helped support the top line.
Adjusted EPS was $2.59
Adjusted earnings per share came in at $2.59. Reported EPS was only $0.09 because of large special charges tied to litigation, acquisitions and strategic transactions.
Investors typically focus on adjusted figures to assess underlying performance.
MedTech missed expectations
The medical-device business generated about $8.6 billion in sales, below analyst expectations. Growth was weaker outside the United States.
Management cited geopolitical disruption, European austerity measures and pricing pressure in China.
Middle East conflict affected device sales
CFO Joe Wolk said some governments in the region were redirecting spending toward defense, reducing demand for premium medical systems.
The company has not yet seen a major direct cost impact from energy prices, but regional sales have weakened.
Pharmaceuticals remained strong
Innovative Medicine sales grew faster, helping offset MedTech weakness. Several newer products posted strong gains.
The drug portfolio remains the company’s largest growth engine.
Tremfya stood out
Tremfya sales rose sharply, helping compensate for declines in older products such as Stelara as competition increases.
This product transition is central to J&J’s long-term pharmaceutical strategy.
Guidance was raised
Management increased its full-year sales and adjusted EPS forecasts. The company expects to exceed $100 billion in annual sales for the first time in its history.
That milestone highlights the scale of the post-Kenvue portfolio.
Orthopedics spin-off remains planned
J&J continues to plan the separation of its DePuy Synthes orthopedics business by mid-2027.
The move is designed to focus MedTech on faster-growing categories.
Innovation remains a key message
The company highlighted regulatory progress for its OTTAVA robotic surgery platform and several pharmaceutical candidates.
Management argues that these launches can drive stronger growth later in the decade.
Investors want faster MedTech improvement
Two consecutive quarters of weaker device performance have increased pressure on management. Raising guidance was positive, but the market wants evidence that international MedTech growth can recover.
The next quarter will be important for showing whether the weakness is temporary or structural.
Sources
- Johnson & Johnson Q3 2026 earnings release
- Reuters, Oct. 13, 2026
The gap between pharmaceuticals and devices is becoming more visible
J&J’s quarter highlights the benefit of owning businesses with different growth drivers. Stronger pharmaceutical demand helped offset weakness in medical technology, but investors are increasingly asking whether the MedTech portfolio can return to faster growth. A diversified structure reduces earnings volatility, yet it can also make underperformance in one division easier to tolerate for too long.
The planned DePuy Synthes separation is part of management’s answer. By removing a slower-growing orthopedics business, J&J wants the remaining device portfolio to focus on higher-growth areas such as surgery, cardiovascular care and robotics.
Geopolitical pressure is affecting healthcare budgets
Management’s comments about the Middle East are notable because they show how military conflict can reach healthcare companies through government spending decisions. Countries facing security pressure may delay purchases of expensive equipment even when long-term medical demand remains strong.
That dynamic could continue if regional tensions persist. Hospitals may postpone capital purchases while maintaining spending on essential medicines, creating a different impact across J&J’s two main divisions.
Guidance gives investors a counterweight
Raising full-year expectations suggests management believes pharmaceutical momentum and other businesses can compensate for device weakness. The key question is whether MedTech improves before investors begin to value the company mainly on its drug pipeline.
J&J’s ability to cross the $100 billion annual-sales threshold would be a significant milestone after years of portfolio restructuring. Investors will watch whether that scale translates into faster earnings growth once special charges fade. The company’s long-term case rests on converting scientific innovation into commercially successful products while improving the consistency of its device business.
